Novartis develops new malaria drug GanLum to combat drug resistance

dostor.org (Arabic)

Novartis announced a new malaria drug, GanLum, showing high efficacy against drug-resistant parasites. GanLum utilizes a novel molecule, ganaplasid, distinct from existing antimalarials, making it effective against artemisinin-resistant strains. Clinical trials showed a 97.4% cure rate. The drug also targets parasite transmission to mosquitoes. Regulatory approval is anticipated within 16 months, potentially making it the first new malaria treatment since 1999.


With a significance score of 4.7, this news ranks in the top 2.4% of today's 31104 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers: